Pancreatic Cancer | Unmet Need | US/EU | 2021
Pancreatic cancer is a difficult-to-treat malignancy, with dismal survival outcomes. First-line treatment of metastatic disease is limited to chemotherapy-based regimens such as FOLFIRINOX and Abraxane with gemcitabine; these therapies offer only modest survival benefits, highlighting the substantial unmet need for more-effective therapies. Targeted therapies such as Tarceva (Roche) and Lynparza maintenance therapy (AstraZeneca) are also approved to treat pancreatic cancer. In this report, we evaluate the performance of key drugs based on user-defined drug attributes and the impact of these attributes on physicians’ prescribing behavior. We also explore attributes that will favor the uptake of novel therapies for this patient population.
QUESTIONS ANSWERED
- What treatment drivers and goals are most likely to influence the choice of therapy for locally advanced or metastatic pancreatic cancer?
- What attributes are key influencers of prescribing, and what are the hidden opportunities for drug developers?
- What are the prevailing areas of unmet need and opportunity in locally advanced and metastatic pancreatic cancer?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European oncologists for a new treatment for first-line locally advanced or metastatic pancreatic cancer?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in July 2021
Key companies: Celgene, AstraZeneca, Roche, Ipsen / Servier
Key drugs: Abraxane, Onivyde, Tarceva, Lynparza, gemcitabine, 5-FU / leucovorin, FOLFIRINOX
